RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Michele Carbone to Antineoplastic Agents

This is a "connection" page, showing publications Michele Carbone has written about Antineoplastic Agents.
Connection Strength

0.370
  1. Carbone M, Rudzinski J, Bocchetta M. High throughput testing of the SV40 Large T antigen binding to cellular p53 identifies putative drugs for the treatment of SV40-related cancers. Virology. 2003 Oct 25; 315(2):409-14.
    View in: PubMed
    Score: 0.141
  2. Napolitano A, Carbone M. Malignant Mesothelioma: Time to Translate? Trends Cancer. 2016 09; 2(9):467-474.
    View in: PubMed
    Score: 0.086
  3. Hillegass JM, Blumen SR, Cheng K, MacPherson MB, Alexeeva V, Lathrop SA, Beuschel SL, Steinbacher JL, Butnor KJ, Ramos-Ni?o ME, Shukla A, James TA, Weiss DJ, Taatjes DJ, Pass HI, Carbone M, Landry CC, Mossman BT. Increased efficacy of doxorubicin delivered in multifunctional microparticles for mesothelioma therapy. Int J Cancer. 2011 Jul 01; 129(1):233-44.
    View in: PubMed
    Score: 0.058
  4. Beck AK, Pass HI, Carbone M, Yang H. Ranpirnase as a potential antitumor ribonuclease treatment for mesothelioma and other malignancies. Future Oncol. 2008 Jun; 4(3):341-9.
    View in: PubMed
    Score: 0.049
  5. Pass HI, Vogelzang N, Hahn S, Carbone M. Malignant pleural mesothelioma. Curr Probl Cancer. 2004 May-Jun; 28(3):93-174.
    View in: PubMed
    Score: 0.037
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support